International medical humanitarian organisation Médecins Sans Frontières (MSF), along with other health groups, reiterated concerns about harmful intellectual property provisions in the proposed agreement that would increase market monopolies for pharmaceutical corporations and delay or block access to affordable generic medicines.
CETA drug-patent extension applies only to new products, and higher costs are likely at least 8 years away
Experts have been warning for years that Canada’s trade deal with the European Union would add billions to the cost of pharmaceuticals in Canada, but the government itself apparently did not study the issue.
US reports that data exclusivity for biologics in Australia could still be extended to 12 years via the TPP trade deal have got local activists up in arms.
The Public Health Association (PHA) is asking the NZ government to step in and help our neighbouring countries negotiate better deals for life-saving medicines.
India and the US continued to differ on the issue of intellectual property rights (IPR) norms in their bilateral trade and investment policy discussions
Access to affordable medicine and farmers’ control over seeds could be undermined by the Regional Comprehensive Economic Partnership being negotiated between Asean member countries and six other trade partners, says FTA Watch in Thailand
95 health, community and development organisations in the Asia Pacific region call on trade negotiators from sixteen countries in the Regional Comprehensive Economic Partnership agreement negotiations to ensure access to medicines is protected. We the undersigned organisations call on negotiators to protect health and reject all TRIPS plus intellectual property measures in the RCEP.
Member countries must consider the impact of RCEP on access to medicines in developing countries
Affordable generics have transformed medical treatment, yet intellectual property provisions in a China-led regional trade deal could block access to life-saving drugs for millions in Africa and Asia
’Unfortunately, trade agreements have become one more mechanism for drug corporations to expand their monopoly power’
Big Pharma is everything but shy when it comes to lobbying EU policy-makers. But what exactly are these groups lobbying for in TTIP?
According to the Bloomberg, Senator Hatch said “They’re going to have to find a way of having the countries agree to change that formality in the TPP to 12 years…If Australia wants to be part of it, they have to meet our terms,”
As the next round of Regional Comprehensive Economic Partnership (RCEP) trade talks begin in Vietnam, humanitarian aid organisation Médecins Sans Frontières calls for the removal of intellectual property provisions from the agreement
Provisions related to evergreening of patents in the proposed Regional Comprehensive Economic Partnership Agreement (RCEP) was dropped after stiff opposition from India, Parliament was informed today.
Adopting a national pharmacare program would offset the higher drug prices expected with the ratification of the Trans-Pacific Partnership, write Tanishq Suryavanshi and Jake Hirsch-Allen.
We call on countries negotiating the RCEP agreement and to protect the flexibilities available under the WTO TRIPS agreement for Least Developed Countries (LDCs).
A high-level panel hosted by India discusses the issues of trade deals that inhibit access to medicines and also limit policy space for governments to legislate in public interest.
The Ministry of Commerce must be cautious of Free Trade Agreements being negotiated with the European Union as well as the Regional Comprehensive Economic Partnership that further strengthen or extend intellectual property (IP) monopolies.
Of the RCEP negotiating countries, it is India, rather than China, that has been the most outspoken in opposing US-style trade rules.